Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice
نویسندگان
چکیده
Oxidative stress, a central mediator of cardiovascular disease, results in loss of the prosthetic haem group of soluble guanylate cyclase (sGC), preventing its activation by nitric oxide (NO). Here we introduce Apo-sGC mice expressing haem-free sGC. Apo-sGC mice are viable and develop hypertension. The haemodynamic effects of NO are abolished, but those of the sGC activator cinaciguat are enhanced in apo-sGC mice, suggesting that the effects of NO on smooth muscle relaxation, blood pressure regulation and inhibition of platelet aggregation require sGC activation by NO. Tumour necrosis factor (TNF)-induced hypotension and mortality are preserved in apo-sGC mice, indicating that pathways other than sGC signalling mediate the cardiovascular collapse in shock. Apo-sGC mice allow for differentiation between sGC-dependent and -independent NO effects and between haem-dependent and -independent sGC effects. Apo-sGC mice represent a unique experimental platform to study the in vivo consequences of sGC oxidation and the therapeutic potential of sGC activators.
منابع مشابه
NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size
AIMS Guanylyl cyclase-cyclic guanosine monophosphate signalling plays an important role in endogenous cardioprotective signalling. The aim was to assess the potential of direct pharmacological activation and stimulation of soluble guanylyl cyclase, targeting different redox states of the enzyme, to limit myocardial necrosis during early reperfusion. METHODS AND RESULTS Rat isolated hearts wer...
متن کاملPharmacological activation of soluble guanylate cyclase activator protects the heart against isoproterenol-induced myocardial ischemia in rats
Background The role of the NO-cGMP-PKG pathway in myocardial protection and preconditioning has been object of intensive investigations. The novel NOand haem-independent soluble guanylate cyclase (sGC)-activator cinaciguat (BAY 58-2667), has been reported to elevate intracellular cGMP concentration and activate the NO-cGMP-PKG pathway in vivo. We investigated the effects of cinaciguat on myocar...
متن کاملFluorescence Dequenching Makes Haem-Free Soluble Guanylate Cyclase Detectable in Living Cells
In cardiovascular disease, the protective NO/sGC/cGMP signalling-pathway is impaired due to a decreased pool of NO-sensitive haem-containing sGC accompanied by a reciprocal increase in NO-insensitive haem-free sGC. However, no direct method to detect cellular haem-free sGC other than its activation by the new therapeutic class of haem mimetics, such as BAY 58-2667, is available. Here we show th...
متن کاملRegulation of soluble guanylate cyclase by matricellular thrombospondins: implications for blood flow
Nitric oxide (NO) maintains cardiovascular health by activating soluble guanylate cyclase (sGC) to increase cellular cGMP levels. Cardiovascular disease is characterized by decreased NO-sGC-cGMP signaling. Pharmacological activators and stimulators of sGC are being actively pursued as therapies for acute heart failure and pulmonary hypertension. Here we review molecular mechanisms that modulate...
متن کاملGenetic mapping of a modifier locus affecting hypertension in soluble guanylate cyclase a1 deficient mice
Background We previously reported that male mice deficient in the a1 subunit of the NO receptor soluble guanylate cyclase (sGCa1 -/mice), an important nitric oxide (NO) receptor, are hypertensive [1]. The phenotype depends on the genetic background: sGCa1 -/mice on a 129S6 (S6) background (sGCa1 ) but not on a C57BL/6 (B6) background (sGCa1 ) develop hypertension [2]. These findings suggest tha...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 6 شماره
صفحات -
تاریخ انتشار 2015